Information Provided By: 
Fly News Breaks for September 28, 2015
SYK, BSX
Sep 28, 2015 | 08:06 EDT
Needham analyst Mike Matson upgraded Boston Scientific (BSX) to Buy from Hold with a $21 price target. A "strong" product cycle will drive revenue growth reacceleration in 2016, Matson tells investors in a research note. Consensus estimates are conservative and the stock is undervalued, he contends. The analyst coupled the upgrade with a downgrade to Hold of Stryker (SYK).
News For BSX;SYK From the Last 2 Days
BSX
Apr 26, 2024 | 05:04 EDT
BSX
Apr 25, 2024 | 09:53 EDT
RBC Capital raised the firm's price target on Boston Scientific to $82 from $78 and keeps an Outperform rating on the shares. Given the company's Q1 momentum on seales and earnings, along with its new product ramp, the management's updated FY24 guidance is likely "conservative" despite easier comps, the analyst tells investors in a research note. RBC adds that the stock is its top pick in the Sector based on its "industry-leading growth profile".
BSX
Apr 25, 2024 | 08:51 EDT
BSX
Apr 25, 2024 | 08:26 EDT
BSX
Apr 25, 2024 | 08:24 EDT
Evercore ISI analyst Vijay Kumar raised the firm's price target on Boston Scientific to $78 from $72 and keeps an Outperform rating on the shares as the firm said the company reported "solid results and there wasn't much to pick on." While EP franchise acceleration driven by Farapulse PFA launch "is generally well known" by the Street, the firm says it doesn't think "anyone expected ~86% US growth and ~72% International growth."
BSX
Apr 25, 2024 | 06:59 EDT
BSX
Apr 25, 2024 | 06:47 EDT
BSX
Apr 25, 2024 | 06:37 EDT
BSX
Apr 25, 2024 | 06:29 EDT
Baird analyst David Rescott raised the firm's price target on Boston Scientific to $84 from $79 and keeps an Outperform rating on the shares. The firm noted its 1Q24 revenue/adjusted EPS beat was the biggest over the past several years and one of the most compelling in diversified LGCP MedTech.
BSX
Apr 25, 2024 | 06:22 EDT
BSX
Apr 24, 2024 | 16:20 EDT
BSX
Apr 24, 2024 | 13:53 EDT
Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.
BSX
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BSX
Apr 24, 2024 | 07:03 EDT
BSX
Apr 24, 2024 | 07:01 EDT
